Dr. Lin Wu is Vice President, Global Head of Assay and Platform Development for Roche Sequencing Solutions, a Business Unit for Roche Diagnostics. She is responsible for reagent, assay, and platform development of Roche Next Generation Sequencing (NGS) systems. Prior to Roche Sequencing, Dr. Wu was Senior Director, Head of Genomics & Oncology Research Department of Roche Molecular Diagnostics. She was responsible for research and early development activities for genetic tests and cancer companion diagnostic tests. Dr. Wu has a strong background in in-vitro diagnostic assay development. She led the development of the first FDA cleared microarray-based pharmacogenetic test, AmpliChip CYP450 (launched in 2004) and assumed various leadership roles during the development of Roche’s cobas oncology portfolio, including the first co-developed companion diagnostic test, cobas BRAF Mutation Test for Zelboraf (launched in 2011) and cobas EGFR Mutation Test for Tarveca (launched in 2013). Dr. Wu pioneered the scientific research work in detecting tumor DNA in blood, which eventually led the launch of cobas EGFR blood assay in 2016, the first liquid biopsy test approved by US FDA.

Dr. Lin Wu received her B.S. from Fudan University in China and her Ph. D. in Molecular Biology from State University of New York at Buffalo. Prior to joining Roche, she completed her post-doctoral fellowship in cancer biology at Princeton University.